Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactogemikan in moderate to severe CKD
NCT06863194Phase 2Recruiting
- Sponsor
- Mansoura University
- Start
- Apr 2025
- Primary completion
- Oct 2025
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Lactogemikan in chronic kidney disease (CKD) (2 arms), sponsored by Mansoura University. Primary endpoints: Estimated Glomerular Filtration Rate at 12 months, Serum Creatinine at 12 months and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
Lactogemikan
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06863194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06863194.